References
Key articles
Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Full text Abstract
Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Abstract
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].Full text
World Health Organization. Manual on case management and surveillance of the leishmaniases in the WHO European Region. July 2017 [internet publication].Full text
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. Abstract
Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Abstract
Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Full text
Reference articles
1. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007 Sep;7(9):581-96. Abstract
2. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov;5(11):873-82. Abstract
3. Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol. 1999 May-Jun;17(3):279-89. Abstract
4. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev. 2001 Oct;14(4):659-88.Full text Abstract
5. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008 Mar;8(3):191-9. Abstract
6. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003 Feb;3(2):87-98. Abstract
7. World Health Organization. The post kala-azar dermal leishmaniasis (PKDL) atlas: a manual for health workers. 2012 [internet publication].Full text
8. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Full text Abstract
9. Cabello I, Caraballo A, Millan Y. Leishmaniasis in the genital area. Rev Inst Med Trop Sao Paulo. 2002 Mar-Apr;44(2):105-7.Full text Abstract
10. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000Res. 2017 May 26;6:750.Full text Abstract
11. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol. 2003 Oct;97 Suppl 1:107-14. Abstract
12. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-76. Abstract
13. Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop. 2008 Jan;105(1):1-9. Abstract
14. Global Health Data Exchange. Global burden of disease study 2019 (GBD 2019) data resources [internet publication].Full text
15. World Health Organization. Fact sheet: leishmaniasis. Mar 2020 [internet publication].Full text
16. World Health Organization. Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014. Wkly Epidemiol Rec.2016:91:287-96.Full text
17. World Health Organization. Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic. Nov 2022 [internet publication].Full text
18. Pan American Health Organization. Leishmaniasis: epidemiological report of the Americas, No. 10 (December 2021). Dec 2021 [internet publication].Full text
19. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008 Apr;21(2):334-59.Full text Abstract
20. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006 Jan;19(1):111-26.Full text Abstract
21. Wright NA, Davis LE, Aftergut KS, et al. Cutaneous leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008 Apr;58(4):650-2. Abstract
22. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004 Feb;53(2):158-66.Full text Abstract
23. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM. 2004 Dec;97(12):781-8. Abstract
24. Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004 Dec 1;39(11):1674-80.Full text Abstract
25. Pan American Health Organization. Leishmaniases. Epidemiological report of the Americas, December 2020. Dec 2020 [internet publication].Full text
26. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.Full text Abstract
27. World Health Organization. WHO responds to visceral leishmaniasis outbreak inKenya. Jun 2017 [internet publication].Full text
28. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006 Dec;22(12):552-7. Abstract
29. Myles O, Wortmann GW, Cummings JF, et al. Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med. 2007 Sep 24;167(17):1899-901. Abstract
30. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002 Aug 1;35(3):261-7.Full text Abstract
31. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and reserve components, U.S. Armed Forces, 2001-2016. MSMR. 2017 Feb;24(2):2-7. Abstract
32. Mody RM, Lakhal-Naouar I, Sherwood JE, et al. Asymptomatic visceral Leishmania infantum infection in US soldiers deployed to Iraq. Clin Infect Dis. 2019 May 30;68(12):2036-44.Full text Abstract
33. Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg Infect Dis. 2006 Mar;12(3):440-6.Full text Abstract
34. Sereno D. Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens. New Microbes New Infect. 2019 Apr 4;30:100540.Full text Abstract
35. Leelayoova S, Siripattanapipong S, Manomat J, et al. Leishmaniasis in Thailand: a review of causative agents and situations. Am J Trop Med Hyg. 2017 Mar;96(3):534-42.Full text Abstract
36. Desbois N, Pratlong F, Quist D, et al. Leishmania (Leishmania) martiniquensis n. sp. (Kinetoplastida: Trypanosomatidae), description of the parasite responsible for cutaneous leishmaniasis in Martinique Island (French West Indies). Parasite. 2014;21:12.Full text Abstract
37. Depaquit J, Kaltenbach ML, Gay F. Visceral leishmaniasis in traveler to Guyana caused by Leishmania siamensis, London, UK. Emerg Infect Dis. 2018 Aug;24(8):1599-600.Full text Abstract
38. Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol. 2005;59:1-75. Abstract
39. Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun. 2002 Dec;70(12):6919-25.Full text Abstract
40. Weirather JL, Duggal P, Nascimento EL, et al. Comprehensive candidate gene analysis for symptomatic or asymptomatic outcomes of Leishmania infantum infection in Brazil. Ann Hum Genet. 2017 Jan;81(1):41-8.Full text Abstract
41. Rogers ME, Ilg T, Nikolaev AV, et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature. 2004 Jul 22;430(6998):463-7. Abstract
42. Vannier-Santos MA, Martiny A, de Souza W. Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des. 2002;8(4):297-318. Abstract
43. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000 Nov;2(14):1765-73. Abstract
44. Belkaid Y, Valenzuela JG, Kamhawi S, et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly? Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6704-9.Full text Abstract
45. Warburg A, Saraiva E, Lanzaro GC, et al. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Philos Trans R Soc Lond B Biol Sci. 1994 Jul 29;345(1312):223-30. Abstract
46. Basu MK, Ray M. Macrophage and Leishmania: an unacceptable coexistence. Crit Rev Microbiol. 2005;31(3):145-54. Abstract
47. Kariyawasam KKGDUL, Selvapandiyan A, Siriwardana HVYD, et al. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies. Parasitology. 2018 Apr;145(4):443-52.Full text Abstract
48. Zhang WW, Ramasamy G, McCall LI, et al. Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog. 2014 Jul;10(7):e1004244.Full text Abstract
49. Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis. 1987 Dec;156(6):1030-3. Abstract
50. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 1999 Aug;13(8):459-65. Abstract
51. Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005 May;11(5):655-62.Full text Abstract
52. Brooker S, Mohammed N, Adil K, et al. Leishmaniasis in refugee and local Pakistani populations. Emerg Infect Dis. 2004 Sep;10(9):1681-4.Full text Abstract
53. Kolaczinski JH, Reithinger R, Worku DT, et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008 Apr;37(2):344-52. Abstract
54. Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):184-8.Full text Abstract
55. Pennisi MG, Cardoso L, Baneth G, et al. LeishVet update and recommendations on feline leishmaniosis. Parasit Vectors. 2015 Jun 4;8:302.Full text Abstract
56. Asfaram S, Fakhar M, Teshnizi SH. Is the cat an important reservoir host for visceral leishmaniasis? A systematic review with meta-analysis. J Venom Anim Toxins Incl Trop Dis. 2019 Jun 10;25:e20190012.Full text Abstract
57. Public Health England. HAIRS risk assessment: canine leishmaniosis. Jan 2022 [internet publication].Full text
58. World Veterinary Association. WVA policies: WVA position statement on Leishmaniosis. Apr 2021 [internet publication].Full text
59. Kopterides P, Mourtzoukou EG, Skopelitis E, et al. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1181-9. Abstract
60. Català A, Roé E, Dalmau J, et al. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015;230(3):204-7.Full text Abstract
61. Arens K, Filippis C, Kleinfelder H, et al. Anti-tumor necrosis factor α therapeutics differentially affect Leishmania infection of human macrophages. Front Immunol. 2018 Jul 31;9:1772.Full text Abstract
62. World Health Organization. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. June 2022 [internet publication].Full text
63. Stockdale L, Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis. 2013 Jun 20;7(6):e2278.Full text Abstract
64. Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011 Apr;11(4):322-5. Abstract
65. Romero GA, Boelaert M. Control of visceral leishmaniasis in Latin America: a systematic review. PLoS Negl Trop Dis. 2010 Jan 19;4(1):e584.Full text Abstract
66. González U, Pinart M, Sinclair D, et al, Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev. 2015 Aug 5;2015(8):CD008736.Full text Abstract
67. Picado A, Singh SP, Rijal S, et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ. 2010 Dec 29;341:c6760.Full text Abstract
68. Chowdhury R, Dotson E, Blackstock AJ, et al. Comparison of insecticide-treated nets and indoor residual spraying to control the vector of visceral leishmaniasis in Mymensingh District, Bangladesh. Am J Trop Med Hyg. 2011 May;84(5):662-7. Abstract
69. Costa CH. How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):232-42.Full text Abstract
70. Sousa-Paula LC, Silva LGD, Sales KGDS, et al. Failure of the dog culling strategy in controlling human visceral leishmaniasis in Brazil: a screening coverage issue? PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0007553.Full text Abstract
71. Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis. 1991 Sep-Oct;13(5):1009-17. Abstract
72. Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis. 2017 May 12;11(5):e0005527.Full text Abstract
73. ClinicalTrials.gov. A study to assess the safety, efficacy and immunogenicity of leishmania vaccine ChAd63-KH in PKDL. Apr 2020 [internet publication].Full text
74. ClinicalTrials.gov. A study of a new leishmania vaccine candidate ChAd63-KH (Leish2a). Jan 2020 [internet publication].Full text
75. Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021 Jul 7;29(7):2366-77.Full text Abstract
76. Boelaert M, Bhattacharya S, Chappuis F, et al. Evaluation of rapid diagnostic tests: visceral leishmaniasis. Nat Rev Microbiol. 2007;5(suppl):S30-9.
77. Escobar MA, Martinez F, Scott Smith D, et al. American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop Doct. 1992;22 Suppl 1:69-78;63-4. Abstract
78. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007 Jan;45(1):21-5.Full text Abstract
79. Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Abstract
80. Sevilha-Santos L, Dos Santos Júnior ACM, Medeiros-Silva V, et al. Accuracy of qPCR for quantifying Leishmania kDNA in different skin layers of patients with American tegumentary leishmaniasis. Clin Microbiol Infect. 2019 Feb;25(2):242-7.Full text Abstract
81. Cota GF, de Sousa MR, Demarqui FN, et al. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012;6(5):e1665.Full text Abstract
82. Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol. 2006 Jul;44(7):2343-7.Full text Abstract
83. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):673-5. Abstract
84. De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg. 2006 Oct;75(4):739-43.Full text Abstract
85. Boelaert M, Rijal S, Regmi S, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg. 2004 Jan;70(1):72-7.Full text Abstract
86. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis. 2000 Oct;31(4):1093-5.Full text Abstract
87. Weigle KA, de Dávalos M, Heredia P, et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg. 1987 May;36(3):489-96. Abstract
88. Kager PA, Rees PH. Splenic aspiration. Review of the literature. Trop Geogr Med. 1983 Jun;35(2):111-24. Abstract
89. Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):505-7. Abstract
90. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005 Jun;72(6):811-4. Abstract
91. Schuster FL, Sullivan JJ. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev. 2002 Jul;15(3):374-89.Full text Abstract
92. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002 Sep;9(5):951-8.Full text Abstract
93. Maurya R, Singh RK, Kumar B, et al. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. J Clin Microbiol. 2005 Jul;43(7):3038-41.Full text Abstract
94. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ. 2006 Oct 7;333(7571):723.Full text Abstract
95. Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev. 2014 Jun 20;2014(6):CD009135.Full text Abstract
96. Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):32-40. Abstract
97. de Assis TS, Braga AS, Pedras MJ, et al. Multi-centric prospective evaluation of rk39 rapid test and direct agglutination test for the diagnosis of visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2011 Feb;105(2):81-5. Abstract
98. Harith AE, Kolk AH, Kager PA, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg. 1987;81(4):603-6. Abstract
99. Iqbal J, Hira PR, Saroj G, et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol. 2002 Feb;40(2):475-9.Full text Abstract
100. Marty P, Lelièvre A, Quaranta JF, et al. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):690-1. Abstract
101. Singh RK. Hyperreactive malarial splenomegaly in expatriates. Travel Med Infect Dis. 2007 Jan;5(1):24-9. Abstract
102. World Health Organization. WHO Guidelines for malaria. Jun 2022 [internet publication].Full text
103. Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006 Sep 23;368(9541):1106-18. Abstract
104. Schaefer KU, Kurtzhals JA, Gachihi GS, et al. A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):471-5. Abstract
105. Davies CR, Llanos-Cuentas EA, Pyke SD, et al. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect. 1995 Apr;114(2):297-318.Full text Abstract
106. Cardo LJ. Leishmania: risk to the blood supply. Transfusion. 2006 Sep;46(9):1641-5. Abstract
107. Centers for Disease Control and Prevention. CDC Yellow Book: health information for international travel - cutaneous leishmaniasis. May 2023 [internet publication].Full text
108. Centers for Disease Control and Prevention. CDC Yellow Book: health information for international travel - visceral leishmaniasis. May 2023 [internet publication].Full text
109. Centers for Disease Control and Prevention. Parasites - leishmaniasis. Jun 2023 [internet publication].Full text
110. Pan American Health Organization. Manual of procedures for leishmaniases surveillance and control in the Americas. Dec 2019 [internet publication].Full text
111. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].Full text
112. World Health Organization. Manual on case management and surveillance of the leishmaniases in the WHO European Region. July 2017 [internet publication].Full text
113. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. Abstract
114. Martínez-Valencia AJ, Daza-Rivera CF, Rosales-Chilama M, et al. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005713.Full text Abstract
115. Dereure J, Duong Thanh H, Lavabre-Bertrand T, et al. Visceral leishmaniasis: persistence of parasites in lymph nodes after clinical cure. J Infect. 2003 Jul;47(1):77-81. Abstract
116. Berman JD. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999 Jan;28(1):49-51.Full text Abstract
117. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 998;76(1):25-32.Full text Abstract
118. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006 Oct 1;43(7):917-24.Full text Abstract
119. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005 Dec;5(12):763-74. Abstract
120. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004 Feb 1;38(3):377-83.Full text Abstract
121. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000 Feb;13(4):243-8. Abstract
122. Carnielli JBT, Crouch K, Forrester S, et al. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. EBioMedicine. 2018 Oct;36:83-91.Full text Abstract
123. Tiwary P, Kumar D, Sundar S. Identification and functional validation of a biomarker for the diagnosis of miltefosine relapse during visceral leishmaniasis. Am J Trop Med Hyg. 2018 Feb;98(2):492-6.Full text Abstract
124. Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother. 2006 Oct;58(4):811-5.Full text Abstract
125. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother. 2005 Feb;55(2):229-33.Full text Abstract
126. Pekelharing JE, Gatluak F, Harrison T, et al. Outcomes of visceral leishmaniasis in pregnancy: a retrospective cohort study from South Sudan. PLoS Negl Trop Dis. 2020 Jan;14(1):e0007992.Full text Abstract
127. Sundar S, Chakravarty J. Antimony toxicity. Int J Environ Res Public Health. 2010 Dec;7(12):4267-77.Full text Abstract
128. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 2001 Nov;6(11):849-54.Full text Abstract
129. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8(4):319-42. Abstract
130. Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007 Aug;77(2):266-74. Abstract
131. Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011 May;118(2):87-96. Abstract
132. Heras-Mosteiro J, Monge-Maillo B, Pinart M, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067.Full text Abstract
133. Pinart M, Rueda JR, Romero GA, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD004834.Full text Abstract
134. Morizot G, Kendjo E, Mouri O, et al. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis. 2013 Aug;57(3):370-80.Full text Abstract
135. López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, et al. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016 Jul 26;16:360.Full text Abstract
136. Cardona-Arias JA, Vélez ID, López-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS One. 2015 May 26;10(5):e0122569.Full text Abstract
137. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. Abstract
138. Sosa N, Pascale JM, Jiménez AI, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019 May 2;13(5):e0007253.Full text Abstract
139. Soto J, Soto P, Ajata A, et al. Topical 15% paromomycin-aquaphilic for Bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clin Infect Dis. 2019 Feb 15;68(5):844-9.Full text Abstract
140. Kim DH, Chung HJ, Bleys J, et al. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3(2):e381.Full text Abstract
141. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One. 2017 Sep 19;12(9):e0184777.Full text Abstract
142. Soto J, Paz D, Rivero D, et al. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2016 Apr;94(4):852-6.Full text Abstract
143. Galvão EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS One. 2017 Oct 9;12(10):e0186117.Full text Abstract
144. Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Abstract
145. Roussel M, Nacher M, Frémont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006 Jun;100(4):307-14. Abstract
146. Lai A Fat EJ, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol. 2002 Nov;41(11):796-800. Abstract
147. Christen JR, Bourreau E, Demar M, et al. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Med Infect Dis. 2018 Jul - Aug;24:31-6. Abstract
148. Soto J, Soto P, Ajata A, et al. Miltefosine combined with intralesional pentamidine for Leishmania braziliensis cutaneous leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018 Nov;99(5):1153-5.Full text Abstract
149. Dorlo TP, Kager PA. Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis. 2008 May 28;2(5):e225.Full text Abstract
150. Machado PR, Rosa ME, Guimarães LH, et al. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clin Infect Dis. 2015 Sep 15;61(6):945-9.Full text Abstract
151. Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Full text
152. Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007 Aug;46(8):848-52. Abstract
153. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis. 2007 Aug 15;45(4):478-82.Full text Abstract
154. Avila-García M, Mancilla-Ramírez J, Segura-Cervantes E, et al. Transplacental transmission of cutaneous Leishmania mexicana strain in BALB/c mice. Am J Trop Med Hyg. 2013 Aug;89(2):354-8.Full text Abstract
155. Cunha MA, Leão AC, de Cassia Soler R, et al. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the New World: a retrospective study. Am J Trop Med Hyg. 2015 Dec;93(6):1214-8.Full text Abstract
156. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007 Feb 1;44(3):350-6.Full text Abstract
157. Osman OF, Oskam L, Zijlstra EE, et al. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment. Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):397-400. Abstract
158. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11;362(6):504-12.Full text Abstract
159. Lucero E, Collin SM, Gomes S, et al. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis. 2015 Apr 2;9(4):e0003699.Full text Abstract
160. Goswami RP, Goswami RP, Das S, et al. Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome™). Am J Trop Med Hyg. 2016 Jan;94(1):93-8.Full text Abstract
161. Pandey K, Pal B, Siddiqui NA, et al. Efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India. Am J Trop Med Hyg. 2017 Nov;97(5):1498-502.Full text Abstract
162. Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635.Full text Abstract
163. Goyal V, Mahajan R, Pandey K, et al. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl Trop Dis. 2018 Oct 22;12(10):e0006830.Full text Abstract
164. Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis. 2015 Oct;28(5):426-37. Abstract
165. Gebreyohannes EA, Bhagvathula AS, Abegaz TM, et al. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018 Oct 19;7(1):108.Full text Abstract
166. Romero GAS, Costa DL, Costa CHN, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005706.Full text Abstract
167. Assis TSM, Rabello A, Cota G, et al. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180272.Full text Abstract
168. Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance programme. Clin Drug Investig. 2017 Mar;37(3):259-72.Full text Abstract
169. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011 Feb 5;377(9764):477-86. Abstract
170. Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21;356(25):2571-81.Full text Abstract
171. Jamil KM, Haque R, Rahman R, et al. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118.Full text Abstract
172. Akuffo H, Costa C, van Griensven J, et al. New insights into leishmaniasis in the immunosuppressed. PLoS Negl Trop Dis. 2018 May 10;12(5):e0006375.Full text Abstract
173. Gajurel K, Dhakal R, Deresinski S. Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients. Clin Transplant. 2017 Jan;31(1). Abstract
174. World Health Organization. WHO technical report series 949: control of the leishmaniases - report of a meeting of the WHO Expert Committee on the control of leishmaniases. 2010 [internet publication].Full text
175. Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988.Full text Abstract
176. Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-Miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-Arm, phase 3 trial. Clin Infect Dis. 2022 Oct 12;75(8):1423-32.Full text Abstract
177. Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013 May 2;7(5):e2195.Full text Abstract
178. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS. 1999 Jun 18;13(9):1063-9. Abstract
179. Delgado J, Macías J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999 Nov;61(5):766-9. Abstract
180. Diro E, Edwards T, Ritmeijer K, et al. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. PLoS Negl Trop Dis. 2019 Feb 21;13(2):e0007132.Full text Abstract
181. Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018 Jan 18;66(3):444-51.Full text Abstract
182. Clemente W, Vidal E, Girão E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015 Jan;21(1):89-95.Full text Abstract
183. Pijpers J, den Boer ML, Essink DR, et al. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - a review and meta-analysis. PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007173.Full text Abstract
184. World Health Organization. Statement on miltefosine - potential ocular disorders in patients treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL). Feb 2022 [internet publication].Full text
185. Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005 Sep;99(6):563-9. Abstract
186. Basher A, Maruf S, Nath P, et al. Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh – a series of four cases. Am J Trop Med Hyg. 2017 Oct;97(4):1111-5.Full text Abstract
187. Moulik S, Chaudhuri SJ, Sardar B, et al. Monitoring of parasite kinetics in Indian post-kala-azar dermal leishmaniasis. Clin Infect Dis. 2018 Jan 18;66(3):404-10.Full text Abstract
188. Ramesh V, Dixit KK, Sharma N, et al. Assessing the efficacy and safety of liposomal amphotericin B and miltefosine in combination for treatment of post kala-azar dermal leishmaniasis. J Infect Dis. 2020 Feb 3;221(4):608-17.Full text Abstract
189. World Health Organization. South Sudan intensifies measures against visceral leishmaniasis to improve health and social well-being of affected populations. Nov 2018 [internet publication].Full text
190. Drugs for Neglected Diseases initiative. Fexinidazole/miltefosine combination (VL). Aug 2016 [internet publication].Full text
191. Drugs for Neglected Diseases Initiative. DNDI-0690. Aug 2019 [internet publication].Full text
192. ClinicalTrials.gov. Single oral dose escalation study of DNDI-0690 in healthy male subjects. Apr 2019 [internet publication].Full text
193. Drugs for Neglected Diseases initiative. R&D portfolio update February 2019: DNDi Leishmaniasis programme. Feb 2019 [internet publication].Full text
194. ClinicalTrials.gov. Safety, tolerability and pharmacokinetics (PKs) investigation of GSK3186899 in healthy subjects. Apr 2020 [internet publication].Full text
195. Alves F, Bilbe G, Blesson S, et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018 Oct;31(4):.Full text Abstract
196. Drugs for Neglected Diseases initiatives. Annual report 2020: medicines for the people. 2020 [internet publication].Full text
197. Buffet PA, Rosenthal E, Gangneux JP, et al; Société de Pathologie Exotique. Therapy of leishmaniasis in France: consensus on proposed guidelines [in French]. Presse Medicale. 2011;40:173-84. Abstract
198. Bailey MS, Green AD, Ellis CJ, et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps. 2005 Jun;151(2):73-80.Full text Abstract
199. Hossain MS, Kumar A, Hossain AFMA, et al. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infect Dis Poverty. 2018 Aug 13;7(1):80.Full text Abstract
200. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004 Mar 1;38(5):612-9.Full text Abstract
201. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006 Aug 1;43(3):357-64.Full text Abstract
Use of this content is subject to our disclaimer